Non-invasive predictive score of fibrosis stages in chronic hepatitis C patients based on epithelial membrane antigen in the blood in combination with routine laboratory markers

Research and Development Department, Biotechnology Research Center, New Damietta City Faculty of Science, Cairo University, Giza Tropical Medicine Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Hepatology Research (Impact Factor: 2.74). 11/2011; 41(11):1075-84. DOI: 10.1111/j.1872-034X.2011.00862.x
Source: PubMed


Aim: The epithelial membrane antigen (EMA) could detect small deposits of liver malignant cells. However, no information exists regarding the use of EMA in patients with chronic hepatitis C (CHC). Therefore, we attempted to evaluate the diagnostic performance of EMA to distinguish patients with different liver fibrosis stages.
Methods: Epithelial membrane antigen was identified in sera of 154 CHC patients using Western blot and enzyme linked immunosorbent assay (ELISA). Multivariate discriminant analysis (MDA) and receiver operating characteristic (ROC) curve analyses were used to create a predictive model including EMA in addition to a panel of routine blood markers. A combination algorithm was developed and validated prospectively in 170 CHC additional patients.
Results: Epithelial membrane antigen at 130 kDa was identified, purified and quantified in sera of CHC patients using ELISA. Based on these encouraging results, we purified and developed a direct ELISA for the quantitation of EMA in sera of CHC. MDA selected a score for the prediction of significant liver fibrosis patients based on measurements of EMA, aspartate aminotransferase to platelet ratio index and albumin. Areas under the ROC curves (AUC) of the score for the three biomarkers were 0.82 for patients with liver fibrosis (F1–F4), 0.86 for significant liver fibrosis (F2–F4), 0.87 for advanced liver fibrosis (F3–F4) and 0.86 for liver cirrhosis (F4). The results of the validation study demonstrated that (74%) of patients could have avoided liver biopsy.
Conclusion: This score was validated for the prediction of liver fibrosis stages and may minimize the need for liver biopsy.

Download full-text


Available from: Mohamed Omran
  • [Show abstract] [Hide abstract]
    ABSTRACT: Many blood tests have been proposed as alternatives to liver biopsy for identifying fibrosis or cirrhosis. To evaluate the diagnostic accuracy of blood tests to identify fibrosis or cirrhosis in patients with hepatitis C virus (HCV) infection. MEDLINE (1947 to January 2013), the Cochrane Library, and reference lists. Studies that compared the diagnostic accuracy of blood tests with that of liver biopsy. Investigators abstracted and checked study details and quality by using predefined criteria. 172 studies evaluated diagnostic accuracy. For identifying clinically significant fibrosis, the platelet count, age-platelet index, aspartate aminotransferase-platelet ratio index (APRI), FibroIndex, FibroTest, and Forns index had median positive likelihood ratios of 5 to 10 at commonly used cutoffs and areas under the receiver-operating characteristic curve (AUROCs) of 0.70 or greater (range, 0.71 to 0.86). For identifying cirrhosis, the platelet count, age-platelet index, APRI, and Hepascore had median positive likelihood ratios of 5 to 10 and AUROCs of 0.80 or greater (range, 0.80 to 0.91). The Göteborg University Cirrhosis Index and the Lok index had slightly lower positive likelihood ratios (4.8 and 4.4, respectively). In direct comparisons, the APRI was associated with a slightly lower AUROC than the FibroTest for identifying fibrosis and a substantially higher AUROC than the aspartate aminotransferase-alanine aminotransferase ratio for identifying fibrosis or cirrhosis. Only English-language articles were included, and most studies had methodological limitations, including failure to describe blinded interpretation of liver biopsy specimens and inadequate description of enrollment methods. Many blood tests are moderately useful for identifying clinically significant fibrosis or cirrhosis in HCV-infected patients. Agency for Healthcare Research and Quality.
    No preview · Article · Jun 2013 · Annals of internal medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to evaluate and judge a fibrotic stage of patients with chronic hepatitis C, multivariate regression analysis was performed using multiple fibrosis markers. A total of 581 patients from 8 Hepatology units and institutes were diagnosed by needle biopsy as having chronic liver disease caused by hepatitis C virus. Twenty-three variables and their natural logarithmic transformation were employed in the multivariate analysis. Multivariate regression analysis finally obtained the following function: z=2.89 x ln(type IV collagen 7S)(ng/ml) - 0.011 x (platelet count)(x10(3) /mm(3) ) + 0.79 x ln(total bilirubin)(mg/dl) + 0.39 x ln(hyaluronic acid)(microgram/L) - 1.87. Median values of the "fibrosis score" of F1 (N=172), F2 (N=80), F3 (N=37), and F4 (N=16) were calculated as 1.00, 1.45, 2.82, and 3.83, respectively. Multiple regression coefficient and coefficient of determination were 0.56 and 0.320, respectively. Validation with patient data from other institutions demonstrated good reproducibility of the "fibrosis score" for hepatitis C (FSC), showing 1.10 in F1 (N=156), 2.35 in F2 (N=73), 3.16 in F3 (N=36), and 3.58 in F4 (N=11), respectively. A concise multiple regression function using four laboratory parameters successfully predicted pathological fibrosis stage of patients with hepatitis C virus infection. (195 words).
    No preview · Article · Aug 2013 · Hepatology Research
  • [Show abstract] [Hide abstract]
    ABSTRACT: Immunohistochemical studies proved that the presence of breast cancer (BrCa) is accompanied by elevated levels of epithelial membrane antigen (EMA) and decreased levels of cytokeratin-1 (CK1). We, therefore, hypothesize that the serum EMA/CK1 ratio may serve as a promising biomarker for early diagnosis of breast cancer. The circulating levels of EMA and CK1 were determined by Western blot and enzyme-linked immunosorbent assay (ELISA) in sera from 102 women with BrCa and 90 women as controls (40 with benign breast disease and 50 healthy). EMA at 130 kDa and CK1 at 67 kDa were identified, purified, and quantified in sera of BrCa patients using ELISA. EMA/CK1 ratio values were found to discriminate BrCa patients from controls (P < 0.0001) with high diagnostic ability (area under the curve [AUC] = 0.901, sensitivity = 82, specificity = 76). The sensitivity and specificity for early-stage (≤T2) BrCa were 72 and 76 %, respectively. The ratio values of patients with late-stage (>T2) tumors were significantly higher than those of patients with early-stage (≤T2) tumors. Moreover, higher grades (grades 2-3) were associated with higher values than grade 1 tumors. AUC values in different BrCa patients who had early stage, low grade, or size ≤2 cm were 0.855, 0.762, and 0.839, respectively. AUC values of patients with positive lymph node or positive distant metastasis were 0.907 and 0.913, respectively. We show for the first time the impact of serum EMA and CK1 ratio in BrCa detection. Differential EMA/CK1 values may serve as a diagnostic marker in early-stage breast cancer patients.
    No preview · Article · Jul 2014 · Tumor Biology